Literature DB >> 19107637

Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.

Annette W Fothergill1, Michael G Rinaldi, Deanna A Sutton.   

Abstract

Frequently, diseases caused by black yeasts are chronic in nature with a high morbidity. In addition, these infections are often fatal and relapse is common, even after prolonged treatment. Although the CLSI Document M38-A outlines methods for antifungal susceptibility testing of moulds, Exophiala spp. are not directly discussed. In an effort to determine the antifungal susceptibility patterns of Exophiala spp. we tested 160 clinical isolates against amphotericin B, itraconazole, posaconazole, and voriconazole in a head-to-head comparison. Posaconazole and itraconazole were the most active in vitro with MICs falling well below the achievable serum levels typically observed with standard dosing regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19107637     DOI: 10.1080/13693780802512451

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  17 in total

1.  In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.

Authors:  Sharon C-A Chen; Chayanika Biswas; Robyn Bartley; Fred Widmer; Namfon Pantarat; Daniel Obando; Julianne T Djordjevic; David H Ellis; Katrina A Jolliffe; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.

Authors:  S Seyedmousavi; K Samerpitak; A J M M Rijs; W J G Melchers; J W Mouton; P E Verweij; G S de Hoog
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

Review 4.  Black yeasts and their filamentous relatives: principles of pathogenesis and host defense.

Authors:  Seyedmojtaba Seyedmousavi; Mihai G Netea; Johan W Mouton; Willem J G Melchers; Paul E Verweij; G Sybren de Hoog
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  In Vitro Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi.

Authors:  Hailin Zheng; Nana Song; Huan Mei; Jiacheng Dong; Dongmei Li; Xiaofang Li; Weida Liu
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 6.  Black Molds and Melanized Yeasts Pathogenic to Humans.

Authors:  Anuradha Chowdhary; John Perfect; G Sybren de Hoog
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 7.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

8.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

9.  Isolation and antifungal susceptibility of Exophiala dermatitidis isolates from human stool samples in Nigeria.

Authors:  E I Nweze; S Ezute
Journal:  Mycopathologia       Date:  2009-10-17       Impact factor: 2.574

10.  Cutaneous and mucosal phaeohyphomycosis caused by Exophiala spinifera in a pregnant patient: case report and literature review.

Authors:  Le Wang; Xiaodong She; Guixia Lv; Yongnian Shen; Qing Cai; Rong Zeng; Caixia Li; Yiping Ge; Shuwen Deng; G S de Hoog; Min Li; Weida Liu
Journal:  Mycopathologia       Date:  2013-01-20       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.